Alogliptin May Be Associated With Lower Fracture Risk Compared With Linagliptin, Saxagliptin
The DPP-4 inhibitor alogliptin may be associated with a lower risk for bone fracture compared with linagliptin and saxagliptin.
In the Biologics License Application (BLA) resubmission, Amgen and UCB proposed to narrow the indication to treatment of osteoporosis in postmenopausal women at high risk of fracture.
Denosumab inhibits osteoclast formation and activity in cortical bone, and this mechanism of action may be reﬂected by the reduction of erosion in both depth and surface.
The need for effective osteoporosis screening tools and treatment strategies is high, as the current methods have a low sensitivity for determining postmenopausal women at risk for a major osteoporotic ...